Rosebank Industries (LSE:ROSE) was created to do one thing: buy underperforming industrial businesses, fix them and eventually sell them at a profit. Led by the team that built the FTSE 100 group Melrose, it is asking investors to back a proven playbook applied to a fresh set of companies.

In 2026 that plan moved from promise to practice, with a transformational pair of acquisitions announced and funded.

The buy, improve, sell model

Rosebank's strategy is to acquire industrial companies whose margins lag their potential, apply operational and management improvements, and then return the value created to shareholders, typically by selling the improved business. Management targets 6 to 7 percentage points of operating-margin improvement at each acquisition.

Its first deal was Electrical Components International, or ECI, a maker of wiring harnesses and electrical distribution systems, bought in 2025. The approach borrows directly from Melrose, whose founders lead Rosebank, and depends entirely on management's skill at picking the right targets and executing the turnaround.

The Melrose pedigree is central to the pitch. Over two decades that team bought and improved industrial names such as Elster and Nortek, and ultimately the aerospace and automotive parts maker GKN, generating substantial gains for shareholders before returning cash. Rosebank is asking investors to trust that the same disciplined operational playbook can be repeated on a new canvas.

“Buy, improve, sell” sounds simple, but each stage demands hard judgement: paying a sensible price, driving genuine operational change rather than mere cost-cutting, and timing disposals to a receptive market. Get those right and the returns can be large; get them wrong and the Leverage bites.

A transformational double deal

In March 2026 Rosebank agreed to acquire two US industrial groups, MW Components and CPM, for a combined $3.05bn, at roughly 10 and 12 times their 2025 Earnings before interest, tax, Depreciation and amortisation. The purchases were funded by a £1.9bn underwritten Equity raise at £3.30 a share, new Debt facilities targeting leverage of about 2.75 times earnings, and a retail offer.

For its 2025 financial year, including a few months of ECI, Rosebank reported adjusted Revenue of $445m, adjusted operating profit of $57m and adjusted diluted earnings of 17.8 cents, with net debt of $494m. The company also moved up from London's junior AIM market to the Main Market and entered the FTSE 250.

Why the risks are substantial

The model is high-risk by design. Success rests on buying well, improving operations and selling at the right time, and any misstep, an overpaid acquisition, a botched turnaround or a weak market for disposals, can destroy value rather than create it. The enlarged group also carries meaningful debt, which magnifies both gains and losses.

Rosebank is, in effect, a bet on its managers. Their Melrose record is impressive, but past success is no guarantee, and the concentrated portfolio means a single problem asset could weigh heavily on returns.

What to watch next

Investors should track the integration of MW Components and CPM, the Margin improvements actually delivered, the path of net debt, and ultimately the prices achieved when businesses are eventually sold. Any further acquisitions will show how quickly management wants to build the group.

Rosebank offers a concentrated wager on a well-honed industrial playbook, now backed by Real assets and real leverage. The potential rewards are considerable if the turnarounds work as intended, but this is a Business whose value will be proven only over years, through the full cycle of buying, improving and selling. In short, Rosebank is a leveraged bet on a proven but small team repeating a rare and demanding feat on a much larger, more public stage, and investors should size their exposure with that concentration, execution risk and debt firmly in mind.